StockData
Cadrenal Therapeutics, Inc. logo

Cadrenal Therapeutics, Inc. (CVKD) stock

CVKDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 9/30
$1.70+0.01 (+0.59%)

Close on Nov 20, 2026Market cap $6.06MP/E –Yield 970.59%

Cadrenal Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Cadrenal Therapeutics's free cash flow for the twelve months ending Dec 31, 2025 was -$12.61M. For fiscal 2025 it was -$12.61M.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$12.61M–
FY2024Dec 31, 2024-$7.36M–
FY2023Dec 31, 2023-$3.53M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025-$2.57M–
Q3 FY2025Sep 30, 2025-$2.36M–
Q2 FY2025Jun 30, 2025-$3.03M–
Q1 FY2025Mar 31, 2025-$4.65M–
Q4 FY2023Dec 31, 2023-$694.45K–

More Cadrenal Therapeutics figures

See a number that looks wrong?